Crossmark

In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity

Crossref DOI link: https://doi.org/10.1038/s41423-018-0087-y

Published Online: 2018-07-20

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cottagiri, Merylin

Nyandjo, Maeva

Stephens, Matthew

Mantilla, Joel J. http://orcid.org/0000-0002-4624-7231
Saito, Hirohisa

Mackay, Ian R.

Rose, Noel R.

Njoku, Dolores B. http://orcid.org/0000-0002-5458-4596
Funding

Funding for this research was provided by:

The American Autoimmune Related Disease Association, and Mr. and Mrs. Joseph Scoby and the Gail I Zuckerman Foundations
License Information

Text and Data Mining valid from 2018-07-20
More Information

Article History

Received: 11 January 2018

Accepted: 6 June 2018

First Online: 20 July 2018

Conflict of interest

: Ms. Cottagiri declares no potential conflict of interest. Ms Nyandjo declares no potential conflict of interest. Mr. Stephens declares no potential conflict of interest. Mr. Mantilla declares no potential conflict of interst. Dr. Saito declares no potential conlict of interest. Dr. Mackay delarees no potential conflict of interest. Dr. Rose declares no potential conflict of interest. Dr. Njoku owns a patent on the epitope utilized in this manuscript. There are no financial relationships or compensations associated with this patent.

Document is current

Any future updates will be listed below